Genmab — Juli 2016
-
ilm - og næste uge kan næsten kun blive bedre!
-
VI HÅBER -
-
The Best Blood Cancer Drug Launch Ever?
Last night, Pharmacyclics reported a quarterly loss of 26 cents per share, far higher than the 11 cents forecast by Wall Street analysts, as it paid $50 million to Johnson & Johnson to help cover the launch of its cancer drug Imbruvica, which J&J co-markets. But the focus among long-term [...]
Forbes (www.forbes.com)
-
Og tallene for imbruvica nævnt der er vist ytd q3 tal, så vidt jeg kan se...
-
Pcyc havde også en lang sløj periode kursmæssigt efter approval. Mon ikke også vi får et stærkt comeback i efteråret, når EU kommer, US penetrerer yderligere og off label har lift off?
-
Godmorgen :-). Ligner en god sommerdag...
-
Gazyva CHOP fejler mod R CHOP. http://www.roche.com/investors/updates/inv-update-2016-07-18.htm
-
hmm - det er da lidt af en overraskelse
-
gade vide om den hexabody GEN pusler med som IND er en cd20...?
-
rituxan har jo vist sig som lidt af en monster "incumbent" på cll, dlbcl etc markedet. Drømmen i sin tid med ofa var vel at vippe rituxan af pinden, og det er ikke rigtigt lykkedes for nogen endnu
-
et medikament, der kan gå head-to-head med rituxan og slå det vil nok have en stor plads på markedet
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind